Wwedbush raised its price target on shares of Anacor Pharmaceuticals Inc. (ANAC) Friday morning to $20 from $10. Anacor reported positive results from a Phase 2 dose-ranging trial of its topical boron-based phosphodiesterase-4 inhibitor, AN2728 on Thursday.
Anacor Pharmaceuticals gapped open higher Friday and has spiked to the upside in early trade. The stock is now up 1.69 at $6.53 on above average volume and has surged to a 5-month high.
For comments and feedback: editorial@rttnews.com